Category - News

Developments

Oramed partner in China moving oral insulin to regulatory approval

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) strategic partner, Hefei Tianhui Biotechnology, successfully completed its Phase 3 trials of oral insulin in Type 2 diabetes patients in China under a differentiated study...

May 15, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Developments

POINT invests in alpha-emitting Isotope maker

POINT Biopharma Global (NASDAQ:PNT) and IONETIX are collaborating to create Ionetix Alpha Corp., a new subsidiary of IONETIX, to focus on near-term, commercial-scale production of GMP-grade therapeutic isotopes, such as...

May 15, 2023

Developments

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

The last patient has completed blinded treatment in Bellerophon Therapeutics’ (NASDAQ:BLPH) Phase 3 REBUILD study of INOpulse, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic...

May 11, 2023

Markets

BTIG cuts Babylon Health on earnings, cash, go-private transaction

BTIG downgraded Babylon Health (NASDAQ:BBLN) to “sell” from “neutral” with a price target of zero, reflecting concerns around earnings, cash flow and cash needs, and the structure of a possible go-private transaction...

May 11, 2023

Markets

BTIG cuts CareDx to hold on CMS policy changes; removal of guidance

BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...

May 11, 2023

Markets

Research Capital bullish on Theralase bladder cancer data

Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) data generated to date shows that Ruvidar’s efficacy is “strong and durable” for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and...

May 10, 2023

Developments

Review committee recommends Addex continue epilepsy study

An independent interim review committee (IRC), following review of unblinded data from Part 1 of patient Cohort 1, recommended Addex Therapeutics (SIX, NASDAQ:ADXN) continue with the ADX71149 Phase 2 epilepsy clinical...

May 10, 2023

Developments

Sweden Orphan Biovitrium to acquire CTI BioPharma

Sweden Orphan Biovitrium (STO:SOBI) entered into a definitive agreement to acquire CTI BioPharma (NASDAQ:CTIC) for $9.10 a share in cash, representing an implied equity value of approximately $1.7-billion. The...

May 10, 2023

Developments

Theralase updates Phase 2 bladder cancer study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) updated recently reported interim clinical data from a Phase 2 clinical study of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle Invasive Bladder...

May 10, 2023

Category - News

Subscribe